BPC 157 in vitro stability needs a little context
Stable sounds reassuring. With BPC-157, it helps to finish the sentence: stable in what, for how long, and under which conditions? That's where this question gets useful.
Stable in what?
In vitro means outside a living body, usually in a lab. Stability is about how well a substance stays intact in a particular setting. The liquid, temperature and length of the test matter. A claim that leaves those out is missing most of its meaning.
BPC-157 is a lab-made chain of fifteen protein building blocks, based on part of a protein reported in stomach juice. That origin doesn't tell us how a stored preparation will hold up. It also doesn't answer what happens after the substance enters a body.
The body asks another question
Researchers tracked BPC-157 in rats and dogs after giving it into a vein or muscle. Its elimination half-life was under thirty minutes: the concentration of intact BPC-157 in the blood fell by half within that time. It also broke down quickly into smaller pieces.
That's an animal finding about how the body clears it. It gives us no human dosing schedule, storage rule or answer about GLOW. How long something stays measurable and how long an effect lasts are separate questions. One number can't do both jobs.
Did the tendon work better?
A rat Achilles-tendon study found better healing after the tendon had been cut right through. Researchers measured strength and function as well as how the tissue looked. Those are useful things to measure when the subject is repair.
The finding still belongs to rats with that particular injury. It can't tell you whether a long-standing tendon problem in a person will improve. The FDA's review of BPC-157 leaves human safety and effectiveness unresolved. A convincing animal result doesn't finish that work.
Stable doesn't mean safe
The FDA flags possible immune reactions and impurities in BPC-157 preparations. It says there isn't enough safety information to know whether it would harm people. That's a reason to keep the uncertainty visible, rather than let the word stable stand in for safe.
On the FDA page current as of April 22, 2026, BPC-157 is listed under withdrawn nominations, rather than Category 2. Withdrawal isn't FDA clearance or permission to compound it. The safety warning remains beside the entry.
For a care conversation, the useful question is what evidence fits the actual condition. Our GLOW page explains why putting BPC-157 in a blend adds another question, rather than an answer.